Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients

PURPOSE: Resistance to cetuximab, a monoclonal antibody against the epithelial growth factor receptor (EGFR), in colorectal cancer (CRC) may result from compensatory signaling through ErbB receptors, ErbB2/neu/HER2 (HER2) and ErbB3/HER3 (HER3). Pertuzumab is a monoclonal antibody that blocks HER2 he...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rubinson, Douglas A., Hochster, Howard S., Ryan, David P., Wolpin, Brian M., McCleary, Nadine Jackson, Abrams, Thomas A., Chan, Jennifer A., Iqbal, Syma, Lenz, Heinz J., Lim, Dean, Rose, Jeffrey, Bekaii-Saab, Tanios, Chen, Helen X., Fuchs, Charles S., Ng, Kimmie
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3775976/
https://ncbi.nlm.nih.gov/pubmed/23568716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-9956-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak